Mortality from lymphohaematopoietic cancers and estimated exposure to styrene, International Agency for Research on Cancer cohort of reinforced plastics workers exposed to styrene, 1945–1991
| NHL (n=24) | Multiple myeloma (n=8) | Myeloid leukaemia* (n=15) | |||||||
| RR† | 95% CI† | AIC | RR | 95% CI | AIC | RR | 95% CI | AIC | |
| Cumulative styrene exposure (100 ppm-years) | |||||||||
| 0-year lag | 1.02 | 0.94 to 1.10 | 488.2 | 0.82 | 0.54 to 1.26 | 179.7 | 0.90 | 0.73 to 1.10 | 314.6 |
| 5-year lag† | 1.02 | 0.94 to 1.11 | 488.2 | 0.87 | 0.59 to 1.27 | 180.3 | 0.91 | 0.73 to 1.12 | 315.1 |
| 10-year lag | 1.03 | 0.94 to 1.12 | 488.1 | 1.69 | 0.30 to 1.62 | 179.5 | 0.88 | 0.66 to 1.17 | 315.0 |
| Mean styrene exposure (100 ppm) | |||||||||
| 0-year lag | 2.31 | 1.29 to 4.12 | 480.3 | 1.86 | 0.71 to 4.86 | 179.6 | 0.92 | 0.37 to 2.32 | 316.1 |
| 5-year lag† | 2.29 | 1.33 to 3.93 | 479.6 | 2.25 | 0.92 to 5.48 | 178.1 | 1.34 | 0.61 to 2.94 | 315.6 |
| 10-year lag | 1.78 | 1.05 to 3.02 | 484.2 | 1.31 | 0.48 to 3.58 | 180.9 | 1.50 | 0.71 to 3.17 | 315.1 |
*Includes acute myeloid leukaemia and chronic myeloid leukaemia.
†RR per 100 ppm-year or 100 ppm; RRs adjusted as follows: NHL, multiple myeloma, age, calendar decade, sex; myeloid leukaemia, age, calendar year, sex, country.
AIC, Akaike information criterion; NHL, non-Hodgkin’s lymphoma; RR, rate ratio.